5432752026-04-012026-06-305432752026-04-012026-06-30in-capmkt:OtherExpenses1Member5432752026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15432752026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-142026-08-10INRMillionsQuarterlyFirst quarterSingle segmentManufacturing of Industrial Chemicals2026-08-1408:48:002026-08-1409:36:00Not applicable2026-04-012026-06-30UnauditedConsolidated6549800000125650000667545000035389300000-69199000064884000049192000056062000014303200005978640000696810000069681000010940000075260000184660000051215000000005121500002780000514930000386390000125760000443540000713900001138480000103.393.39003.393.391. The above Consolidated Financial Results for the quarter ended June 30, 2026, have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter, are approved and taken on record by the Board of Directors in its meeting held on August 14, 2026. <br /> 2. Based on the management approach as defined in Ind AS 108 Operating Segments, the Chief Operating Decision Maker CODM evaluates the companys performance and allocates resources based on an analysis of various performance indicators of business segments in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence, disclosure of segment wise information is not required and accordingly not provided. <br /> 3. Amount includes Rs. 54.37 million being reclassification of foreign exchange difference of foreign operation relating to NCI. <br /> 4. The Company has investment in the following Subsidiary companies including step down subsidiaries and into an Associate Company of Wholly owned subsidiary through a WOS as on June 30, 2026 and accordingly, Consolidated Financial Results for the Quarter ended June 30, 2026 include following entities <br /> Name of the Company Nature of relationship <br /> a. Jainam Intermediates Private Limited Wholly owned subsidiary <br /> b. Tanfac Industries Limited Subsidiary Company over which the Company exercises effective control <br /> c. ARIL Transmodal Logistic Private Limited Wholly owned subsidiary <br /> d. ARIL Fluorospeciality Private Limited Wholly owned subsidiary <br /> e. Anupam Japan GK Wholly owned subsidiary <br /> f. Anupam Europe AG Wholly owned subsidiary <br /> g. Anupam USA LLC Wholly owned subsidiary <br /> h. Anupam General Trading FZE Wholly owned subsidiary <br /> i. Tangent Science Private Limited An Associate Company of Wholly owned subsidiary of the Company <br /> j. Doriath S.a.r.l Wholly owned subsidiary <br /> j1. Monitchem Kansas S.a.r.l Step Down Subsidiary Level I of Wholly owned subsidiary <br /> j2. Kansas Hold Co. Step Down Subsidiary Level II of Wholly owned subsidiary <br /> j3. Kansas Hold Co. 1 Step Down Subsidiary Level III of Wholly owned subsidiary <br /> j4. Jayhawk Fine Chemicals Corporation Step Down Subsidiary Level IV of Wholly owned subsidiary <br /> Monitchem Kansas S.a.r.l has been Liquidated with effect from June 30, 2026. For the Quarter ended June 30, 2026 its Unaudited Interim Financial Results of such subsidiary have been incorporated in its parent entity. Although Liquidated, for appropriate disclosure, its Relationship with the Company has been defined as Step down Subsidiary Level I of Wholly Owned Subsidiary. <br /> 5. The figures of the last quarter as reported are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the previous financial year end and the figures upto the end of third quarter had only been reviewed and not subject to audit. <br /> 6. The figures of the previous period have been re grouped rearranged and or recasted wherever considered necessary.Other Expenses1430320000Gain/(loss) on remeasurements of the defined benefits plan15420000Income tax (expense)/income on remeasurements of the defined benefits plan-3880000115400000Effective portion of gain/(loss) on FCTR / hedging instruments in a cash flow hedge-8380000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge-380000-876000002780000